Opinion|Videos|January 27, 2025
Comparing Venetoclax-Ibrutinib, Venetoclax-Obinutuzumab, and BTKi Options
Panelists discuss the role of ven-ibr in patient populations.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is role of ven-ibr in these patient populations?
- When may you opt for this approach over other time-limited therapy options (ven-obi) or continuous BTKi therapy?
Advertisement
Related to this article
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
The FDA has approved pirtobrutinib for the treatment of adult patients with previously untreated CLL or SLL harboring no known 17p deletion.
The NMPA has approved pirtobrutinib in treatment-naive and previously treated CLL/SLL.
The top 5 OncLive TV videos of the week cover insights in breast cancer, PV, myeloma, and CLL.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
2
FDA Grants Breakthrough Device Designation to Natera’s Multi-Cancer Early Detection Assay
3
VIR-5500 Receives FDA Fast Track Designation in mCRPC
4
MAVERICK, B7-H3–Directed ADCs, and ADAURA Data Headline Key Lung Cancer Findings From WCLC 2026
5